Loading
A phase 3 trial testing Rocbrutinib in chronic lymphocytic leukaemia, now recruiting.
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL is a phase 3 interventional study registered as NCT07342478, led by Newave Pharmaceutical, and recruiting on the registry. Official title: A Phase 3 Open-Label, Randomised, Multicenter Study of Rocbrutinib (LP-168) vs Pirtobrutinib in Covalent BTK Inhibitor (cBTKi) Pretreated Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL) Subjects. Planned enrolment is 306 participants (estimated). The study started in 2026-04-23 and primary completion is expected in 2029-10-30. No results have been posted on ClinicalTrials.gov.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.